|
The Cochrane Collaboration
Cochrane Reviews |
| Explore | New + Updated | Other languages |
|
 |
Pregabalin add-on for drug-resistant partial epilepsyLozsadi D, Hemming K, Marson AG
Bookmark this:
     more ...
SummaryPregabalin add-on for drug-resistant partial epilepsyUse of pregabalin in combination with other antiepileptic drugs can reduce the frequency of seizures, but has some adverse effects. Approximately one in 400 people have epileptic seizures that continue despite antiepileptic drug treatment. This review summarizes data from four trials that included a total of 1397 participants. In addition to their usual antiepileptic drugs, participants were selected to take pregabalin (an antiepileptic drug) or an inactive placebo. Results showed that patients taking pregabalin were three to four times more likely to reduce their seizure frequency by more than 50% over a 12-week interval than those taking placebo. Side effects associated with pregabalin included co-ordination problems, dizziness, sleepiness and weight gain. There are no data regarding the longer term effectiveness of pregabalin; this should be investigated in future studies.
This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration, currently published in The Cochrane Database of Systematic Reviews 2010 Issue 1, Copyright © 2010 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
This version first published online:
January 23. 2008 AbstractBackgroundEpilepsy is a common chronic neurological disease with an estimated prevalence of 1% in the United Kingdom. Approximately a third of these people continue to have seizures despite drug treatment. In order to try to improve outcomes a number of new antiepileptic drugs have been developed and pregabalin is one of these. ObjectivesTo summarize evidence from randomized, controlled trials regarding the efficacy and tolerability of pregabalin when used as an add-on antiepileptic drug in treatment-resistant partial epilepsy. Search strategyWe searched the Cochrane Epilepsy Group Specialized Register (July 2007), The Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2007), MEDLINE (Ovid) (1966 to March 2007) and contacted Pfizer Inc (the manufacturers of pregabalin) to identify published, unpublished, and ongoing trials. Selection criteriaWe included randomized controlled double-blind trials comparing pregabalin with placebo for people with drug-refractory partial epilepsy. Outcomes included 50% or greater reduction in seizure frequency, treatment withdrawal for any reason, treatment withdrawal for adverse events, and nature of adverse events. Data collection and analysisTwo review authors (DL and AGM) independently selected and assessed suitable trials and extracted data. Primary analyses were by intention-to-treat (ITT). Results are presented as relative risks (RR) with 95% confidence intervals (CI). Main resultsFour suitable trials (1397 participants) were identified and included in the analysis. Trials tested doses of pregabalin ranging from 50 mg to 600 mg per day. For the primary outcome, 50% or higher seizure reduction was significantly more likely in patients randomized to pregabalin than to placebo (RR 3.56, 95% CI 2.60 to 4.87). A dose response analysis suggested increasing effect with increasing dose. Pregabalin was not significantly associated with seizure freedom (RR 2.73, 95% CI 0.72 to 10.33). Patients were significantly more likely to have pregabalin withdrawn for any reason (RR 1.43, 95% CI 1.11 to 1.85) or for adverse effects (RR 2.47, 95% CI 1.80 to 4.17). Ataxia, dizziness, somnolence and weight gain were significantly associated with pregabalin. Authors' conclusionsPregabalin, when used as an add-on drug for treatment-resistant partial epilepsy, is significantly more effective than placebo at achieving a 50% or greater seizure reduction. Results demonstrate efficacy for doses from 150 mg to 600 mg per day, with no evidence for plateauing of effect at the doses tested. The trials included in this review were of short duration and longer term trials are needed to better inform clinical decision making. |